SGK1 Antibodies

Structure of SGK1

The SGK1 gene encodes a serine/threonine protein kinase with a molecular weight of approximately 49 kDa. This molecular weight shows slight variations among different splicing variants, mainly due to the variable domain.

The SGK1 protein contains approximately 431 amino acids and performs catalytic functions through its kinase domain (located at the C-terminal). The N-terminal region of the protein is rich in regulatory sequences, which are crucial for the activation and localization of the enzyme. The three-dimensional structure of SGK1 exhibits a typical kinase fold, and its activity is precisely regulated by phosphorylation (such as at the Thr256 and Ser422 sites) and binding to cofactors (such as PDK1). A key hydrophobic motif (FM motif) participates in stabilizing its active conformation, while its nuclear localization signal guides the protein's transport between the cytoplasm and the nucleus.

Fig. 1 The emerging roles and mechanisms of SGK1 in cancer growth and metastasis.¹

Key structural properties of SGK1:

• Typical kinase catalytic domain folding
• Regulatory PH domain, responsible for binding to phospholipids and membrane localization
• Hydrophobic motifs (FM motifs) are crucial for maintaining the conformation of kinase activity
• Serine/threonine phosphorylation sites precisely regulate enzymatic activity and stability

Functions of SGK1

The main function of the SGK1 kinase is to act as a cellular signal transduction hub, regulating cell growth, survival, and ion balance. It is also involved in various pathological and physiological processes, including tumor formation and metabolic disorders.

The activity of SGK1 is strictly regulated by a phosphorylation cascade reaction. Its kinetic curve exhibits typical characteristics of an enzymatic reaction, and is positively correlated with the activation of the upstream PI3K/mTOR signaling pathway, making it a key regulatory factor for cells to adapt to environmental changes.

Applications of SGK1 and SGK1 Antibody in Literature

1. Sang, Yiwen, et al. "SGK1 in human cancer: emerging roles and mechanisms." Frontiers in Oncology 10 (2021): 608722. https://doi.org/10.3389/fonc.2020.608722

The study found that germline mutations in the SETD2 gene are associated with neurodevelopmental disorders. The truncation mutations and missense mutations (such as the arginine mutation at position 1740) exhibit different methylation epigenetic characteristics and clinical phenotypes, revealing specific associations between epigenetic, genotypic and phenotypic factors, and suggesting that missense mutations may have a functional gain-of-function mechanism.

2. Li, Xiangdong, et al. "Hepatocyte SGK1 activated by hepatic ischemia-reperfusion promotes the recurrence of liver metastasis via IL-6/STAT3." Journal of Translational Medicine 21.1 (2023): 121. https://doi.org/10.1186/s12967-023-03977-z

The study found that liver ischemia-reperfusion injury promotes the formation of NETs and the infiltration of PMN-MDSCs by activating the SGK1/IL-6/STAT3 signaling axis, thereby exacerbating the recurrence of colorectal cancer after liver metastasis surgery. Inhibiting SGK1 can effectively block this process, providing a new target for preventing and treating postoperative metastasis and recurrence.

3. Zhang, Shujing, et al. "Discovery of herbacetin as a novel SGK1 inhibitor to alleviate myocardial hypertrophy." Advanced Science 9.2 (2022): 2101485. https://doi.org/10.1002/advs.202101485

The research found that the flavonoid compound HBT discovered in the Rhodiola rosea extract can specifically inhibit the SGK1 kinase, effectively reducing myocardial cell hypertrophy, lowering ROS production and calcium ion accumulation, and regulating the FoxO1 signaling pathway. This research provides a new candidate drug molecule for the treatment of pathological cardiac hypertrophy.

4. Wu, Jianzhi, et al. "SGK1 aggravates idiopathic pulmonary fibrosis by triggering H3k27ac-mediated macrophage reprogramming and disturbing immune homeostasis." International journal of biological sciences 20.3 (2024): 968. https://doi.org/10.7150/ijbs.90808

The study found that SGK1 can drive the reprogramming of M2-type macrophages, promoting the release of CCL9 and TGF-β through the GSK3β-TIP60-H3K27ac signaling axis, thereby attracting Th17 cells and activating fibroblasts, and disrupting the immune microenvironment of pulmonary fibrosis. Targeting SGK1 may provide a new strategy for the treatment of idiopathic pulmonary fibrosis.

5. Valinsky, William C., Rhian M. Touyz, and Alvin Shrier. "Aldosterone, SGK1, and ion channels in the kidney." Clinical science 132.2 (2018): 173-183. https://doi.org/10.1042/CS20171525

The research has found that SGK1, as a key downstream target of aldosterone, regulates the expression and function of various renal ion channels such as ENaC, ROMK, and TRPM6/7. It plays a core role in maintaining the homeostasis of ions like sodium, potassium, and magnesium, and is closely related to the occurrence of aldosterone excess syndrome and hypertension.

Creative Biolabs: SGK1 Antibodies for Research

Creative Biolabs specializes in the production of high-quality SGK1 antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom SGK1 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our SGK1 antibodies, custom preparations, or technical support, contact us at email.